Compounds > 2-methyl-5-nitroimidazol-1-ylacetic acid
Page last updated: 2024-12-07

2-methyl-5-nitroimidazol-1-ylacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-methyl-5-nitroimidazol-1-ylacetic acid: human urinary metabolite of metronidazole; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115249
CHEMBL ID3544703
CHEBI ID166515
SCHEMBL ID10920623
MeSH IDM0075223

Synonyms (42)

Synonym
2-(2-methyl-5-nitroimidazol-1-yl)acetic acid
CHEBI:166515
1-carboxymethylmetronidazole
BAS 07867254
1010-93-1
2-methyl-5-nitro-1h-imidazole-1-acetic acid
AKOS000296818
2-methyl-5-nitroimidazol-1-yl-acetic acid
(2-methyl-5-nitro-1h-imidazol-1-yl)acetic acid
STK667281
69ikl472bq ,
ccris 2147
1h-imidazole-1-acetic acid, 2-methyl-5-nitro-
2-methyl-5-nitroimidazol-1-ylacetic acid
unii-69ikl472bq
CCG-122728
niosh/ni3383000
imidazole-1-acetic acid, 2-methyl-5-nitro-
NI33830000
mfcd01721819
2-methyl-5-nitroimidazole-1-acetic acid
SCHEMBL10920623
1-de(2-hydroxyethyl)metronidazole-1-acetic acid
2-(2-methyl-5-nitro-1h-imidazol-1-yl)acetic acid
metronidazoleacetic acid
DTXSID80143626
CHEMBL3544703
2-(2-methyl-5-nitro-1h-imidazol-1-yl)acetic acid, analytical standard
RVEGZXNRNWUYKI-UHFFFAOYSA-N
metronidazole impurity g
Q27264353
BCP32941
2-methyl-5-nitroimidazol-1-ylacetic acid;2-(2-methyl-5-nitro-1h-imidazol-1-yl)acetic acid
2-(2-methyl-5-nitro-imidazol-1-yl)acetic acid
metronidazole acetic acid
CS-0034830
HY-115249
BS-42675
BAA01093
EN300-622260
2-(2-methyl-5-nitro-1h-imidazol-1-yl)aceticacid
Z111458142

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic indices were found to be independent of the dose administered."( Steady-state pharmacokinetics of metronidazole in Crohn's disease.
Eradiri, O; Jamali, F; Thomson, AB, )		0.13

Bioavailability

ExcerptReferenceRelevance
" Bioavailability of the drug was 19 +/- 3% after the vaginal dose as compared to 100 +/- 5% after the oral dose."( Systemic concentrations of metronidazole and its main metabolites after intravenous oral and vaginal administration.
Fredricsson, B; Hagström, B; Nord, CE; Rane, A, 1987)		0.27

Dosage Studied

ExcerptRelevanceReference
" This would suggest that cumulative penetration of metronidazole from the systemic circulation into the peritoneal cavity with dosing every 8 h should lead to adequate concentrations for the treatment of anaerobic peritonitis."( Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis.
Baxter, H; Guay, DR; Jacyk, WR; Meatherall, RC; Penner, B, 1984)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organonitrogen compoundAny heteroorganic entity containing at least one carbon-nitrogen bond.
organooxygen compoundAn organochalcogen compound containing at least one carbon-oxygen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		2.8840C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
tinidazole
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.		2.3720imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole
1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole: human urinary metabolite of metronidazole; structure		2.8840C-nitro compound;
imidazoles
ConditionIndicatedRelationship StrengthStudiesTrials